

PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/135,238 09/135,238
		Filing Date	August 17, 1998
		First Named Inventor	Nolan, Garry P.
		Group Art Unit	1632
		Examiner Name	R. Shykla, Ph.D.
		Attorney Docket Number	A-65635-1/DJB/RMS/DHR
Sheet	of	1	

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.


1060187

RECEIVED

INFORMATION DISCLOSURE CITATION PTO-1449		ATTY. DOCKET NO. A 65635-1/DJB/RMS		SERIAL NO. 09/135,238			
		APPLICANT: NOLAN et al.		FILING DATE August 17, 1998			
		GROUP 1645-1632					
PATENT DOCUMENTS							
EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
RRS	1	Itoh, et al., "The Polypeptide Encoded by the cDNA for human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> , 66:233-243 (1991).					
	2	Yonehara, et al., "A Cell-Killing Monoclonal Antibody (ANTI-Fas) to a Cell Surface Antigen Co-Downregulated with the Receptor of Tumor Necrosis Factor," <i>J. Exp. Med.</i> , 169:1747-1756 (1989).					
	3	Itoh and Nagata, "A Novel Protein Domain Required for Apoptosis," <i>J. Biol. Chem.</i> , 268:10932-10937 (1993).					
	4	Boldin, et al., "A Novel Protein that Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain," <i>J. Biol. Chem.</i> , 270:7795-7798 (1995).					
	5	Chinnaiyan, et al., "FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis," <i>Cell</i> , 8145:505-512 (1995).					
	6	Chu, et al., "A Fas-associated Protein Factor, FAF1, Potentiates Fas-mediated Apoptosis," <i>Proc. Natl. Acad. Sci. USA</i> , 92:11894-11898 (1995).					
	7	Okura, et al., "Protection Against Fas/APO-1- and Tumor Necrosis Factor-Mediated Cell Death by a Novel Protein, Sentrin," <i>J. Immunol.</i> , 157:4277-4281 (1996).					
	8	Sato, et al., "FAP-1: A Protein Tyrosine Phosphatase that Associates with Fas," <i>Science</i> , 268:411-415 (1995).					
	9	Stanger, et al., "RIP: A Novel Protein Containing a Death Domain that Interacts with Fas/APO-1 (CD95) in Yeast and Causes Cell Death," <i>Cell</i> , 8145:513-523 (1995).					
RRS	10	Enari, et al., "Involvement of an ICE-like Protease in Fas-Mediated Apoptosis," <i>Nature</i> , 375:78-81 (1995).					
EXAMINER		RRS		DATE CONSIDERED		10/6/00	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 616516

SHEET 2 OF 3

INFORMATION DISCLOSURE CITATION PTO-1449 		ATTY. DOCKET NO. A-65635-1/DJB/RMS	SERIAL NO. 09/135,238
		APPLICANT: NOLAN et al.	
		FILING DATE August 17, 1998	GROUP 1643 1632
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)			
RPS	11	Enari, et al., "Sequential Activation of ICE-like and CPP32-like Protease During Fas-Mediated Apoptosis," <i>Nature</i> , 380:723-726 (1996).	
	12	Tewari et al., "Fas- and Tumor Necrosis Factor-Induced Apoptosis is Inhibited by the Poxvirus <i>crmA</i> Gene Product," <i>J. Biol. Chem.</i> , 270:3255-3260 (1995).	
	13	Fernandes-Alnemri, et al., "In Vitro Activation of CPP32 and Mch3 by Mch4, a Novel Human Apoptotic Cysteine Protease Containing Two FADD-Like Domains," <i>Proc. Natl. Acad. Sci. USA</i> , 93:7464-7469 (1996).	
	14	Muzio, et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> , 85:817-827 (1996).	
	15	Irmeler, et al., "Inhibition of Death Receptor Signals by Cellular FLIP," <i>Nature</i> , 388:190-195 (1997).	
	16	Srinivasula, et al., "FLAME-1, a Novel FADD-like Anti-Apoptotic Molecule that Regulates Fas/TNFR1-induced Apoptosis," <i>J. Biol. Chem.</i> , 272:18542-18545 (1997).	
	17	Hu, et al., "I-FLICE, a Novel Inhibitor of Tumor Necrosis Factor Receptor-1- and CD-95-Induced Apoptosis," <i>J. Biol. Chem.</i> , 272:17255-17257 (1997).	
	18	Cifone, et al., "Apoptotic Signaling Through CD95 (Fas/Apo-1) Activates an Acidic Sphingomyelinase," <i>J. Exp. Med.</i> , 180:1547-1552 (1994).	
	19	Tian, et al., "Fas-Activated Serine/Threonine Kinase (FAST) phosphorylate TI1 During Fas-Mediated Apoptosis," <i>J. Exp. Med.</i> , 182:865-874 (1995).	
	20	Yang, et al., "Daxx, A Novel Fas-Binding Protein that Activates JNK and Apoptosis," <i>Cell</i> , 89:1067-1076 (1997).	
	21	Richardson, et al., "Fas Ligation Triggers Apoptosis in Macrophages but not Endothelial Cells," <i>Eur. J. Immunol.</i> , 24:2640-2645 (1994).	
	22	Arase, et al., "Fas-Mediated Cytotoxicity by Freshly Isolated Natural Killer Cells," <i>J. Exp. Med.</i> , 181:1235-1238 (1995).	
	23	Berke, "The CTL's Kiss of Death," <i>Cell</i> , 81:9-12 (1995).	
	24	Montel, et al., "Fas Involvement in Cytotoxicity mediated by Human NK Cells," <i>Cell Immunol.</i> , 166:236-246 (1995).	
RPS	25	Klas, et al., "Activation Interferes with the APO-1 Pathway in Mature Human T Cells," <i>Int. Immunol.</i> , 5(6):625-630 (1993).	
EXAMINER		RPS	DATE CONSIDERED 10/6/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 616515

COPY

FOIA(b)(7)(C) (08-00)

Approved for use through 10/17/2002. CMI 0631-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	09/135,328
				Filing Date	August 17, 1998
				First Named Inventor	Nolan, Gary P.
				Group Art Unit	1632
				Examiner Name	R. Shykla, Ph.D.
				Attorney Docket Number	A-65635-1/DP/RTMS/DHR
Sheet	1	of	1		

[illegible][illegible]

Examiner Signature	RLS	Date Considered	10/7/03
--------------------	-----	-----------------	---------

*EXAMINER: Initial if reference uninitialed, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Conservator, the title copy of this form with new information to be applied.

¹ Unique citation designation number. ² See attached *Kind of U.S. Patent Documents*. ³ Enter OQ file that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard NT. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Important: Applicant is to place a checkmark where it English language fluency is sufficient.
Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.